Guidance: Avian influenza: PGD templates

⌂Back To Homepage Subscribe To RSS Feed

Public Health England

January 22

16:52 2021

Print This Article Share it With Friends

Created by Public Health England 0 comments

Oseltamivir for pre and post exposure prophylaxis of avian influenza: PGD template

Ref: PHE publications gateway number 2015363 MS Word Document, 300KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email publications@phe.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Oseltamivir for post exposure prophylaxis of avian influenza A (H5N8): PGD template

Ref: PHE publications gateway number 2016666 MS Word Document, 301KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

Supply of oseltamivir for pre and post exposure prophylaxis of H7N9 avian influenza in adults and children aged one year or older

Ref: GW-323 MS Word Document, 132KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

Details

Oseltamivir for pre and post exposure prophylaxis of non H7N9 and H5N8 avian influenza: PGD template

This PGD template has been developed for use in incidents involving avian influenza strains other than avian influenza A H5N8 and H7N9. The PGD template is to support the supply of oseltamivir for pre and post exposure prophylaxis (PEP) of avian influenza as a public health measure in adults and children aged one year or older. It has been reviewed and updated in January 2021. It is valid from 7 January until 7 July 2022.

Oseltamivir for post exposure prophylaxis of avian influenza A (H5N8): PGD template

This PGD temp



View the original news story

Scroll Back To Top 📄More Articles

Comments

Scroll Back To Top ✎Write Comment

We don't have any comments for this article yet. Why not join in and start a discussion.

Your name:	Your email:
Comments:
Post my comment

GovWire